UBI集團訊息
UBP acquires global marketing authorization for UB-421, an innovative therapeutic antibody drug for AIDS
UB-421 was originally developed by United Biomedical, Inc., and its Asia market rights were authorized to United Biomedical, Inc., Asia in 1998. In 2013, United Biomedical, Inc., Asia established their spin-off, United BioPharma (UBP), and transferred the UB-421 Asia market rights to UBP. Based on Phase II clinical data for UB-421 monotherapy to substitute HAART treatment superior efficacy in HIV/AIDS patients who continually received HAART treatment was demonstrated.
Although current HAART treatment can efficiently reduce the HIV viral load and patients’ mortality rate, the HIV virus cannot be completely eliminated from the patient. Once the patient discontinues the treatment, the latent virus will be reactivated and easily becomes a drug resistant strain. HIV/AIDS patients have to receive drug treatment for the remainder of their lives. Unfortunately, long-term HAART treatment results in several side-effects and complications. There are not any current monotherapies which can efficiently substitute HAART, UB-421 aims to fit the indication of HAART substitution on the market and provide an easy monotherapy option with few side-effects for global AIDS patients. Apart from viral inhibition for HIV infection of host cells UB-421 has the function of immune modulation; therefore, UBP is proceeding to collaborate with an international AIDS research team on the feasibility of UB-421 for functional cure.
About UBP (6471)
UBP was established in September 2013 as a spinoff from United Biomedical, Inc., Asia, and is strategically partnering with Formosa Plastics Group. UBP has an integrated monoclonal antibody drug development platform, and focuses on development, manufacturing, and marketing of innovative monoclonal antibody drugs and biosimilars. With a spirit of “innovation and practicality,” UBP is dedicated to addressing unmet medical needs, thereby improving the health of mankind and economic advancement of Taiwan. For more information, please visit http://www.unitedbiopharma.com
United BioPharma Forward-Looking Statements
The information in this press release should be considered accurate only as of the date of the release. UBP has no intention of updating and specifically disclaims any duty to update the information in this press release. The press release may contain forward-looking statements involving risks and uncertainties and UBP’s actual results may differ materially from those in the forward-looking statements.